The company has developed a technology platform which includes Drug Design (computational chemistry expertise), Synthesis (through both solution and solid phase parallel synthesis) and Analysis of New Chemical Entities (NCEs). The company is also involved in small scale synthesis of peptides and standard.

The core business covers:
1) Pharmaceutical Research Services
2) Medicinal Chemistry Projects
3) Training activities

The company is carring out several medchem research projects that have already led to promising results. Our main research activities focus on :
- lead immunomodulatory compounds stimulating human ?gamma delta T cells
- metalloproteinase inhibitors
- kinases inhibitors
- new modulators of the endocannabinoid system.

Innovative Aspects:
The company can exploit its know-how and expertise in NCEs design and synthesis to offer services in early drug discovery phases as well as to develop its own medchem research projects (patented libraries).

Its approach to drug discovery research projects is based on:
1. rational drug design (hypothesis):
? active site analysis
? in silico studies on protein/ligand co-crystals when avalaible
? pharmacophore design and screening of C4T 3D virtual database
? C4T database docking in protein active site
? rational compound/selection based on the following criteria: docking and pharmacophore screening; physico-chemical properties;

2. solid/solution phase parallel synthesis

The main innovative features of the company's drug discovery approach rely on:
1. the proprietary 3D database of 8 million of compounds
2. its chemitech platform
3. a young and skilled research group

The research strategy allows the company to identify new hits and optimize lead compounds.

 

Patents/Rights: Patent(s) granted

Type of Organisation: